Henrik Parker

Popular Topics

DETAILS

United States

+1 216 6210200

AUTHORS CONTENT

Federal Circuit Confirms That The BPCIA Always Requires Post-Licensure Notice

United States IP

Federal Circuit Confirms Both New Biosimilar Bring-To-Market Procedural Option And Additional Six-Month Exclusivity Period For Brand-Name Biologics

United States Healthcare

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More